Juan Lama: New HIV Cure Approach Forces Hidden Virus into Tripping Immune Sensor
Juan Lama, Founder and Chief Scientific Officer at RetroVirox Inc., shared a post on LinkedIn:
“New HIV Cure Approach Forces Hidden Virus into Tripping Immune Sensor
The brief News article comments on the new HIV cure approach recently presented at the Conference on Retroviruses and Other Opportunistic Infections (CROI).
The strategy relies on one of the many internal sensors T cells and macrophages use to detect microbes, CARD8 (Caspase Recruitment Domain-containing protein 8).
CARD8 detects key viral enzymes called proteases, and it triggers an inflammatory form of cell death known as pyropptosis that avoids the production of infectious particles.
In HIV expressing cells CARD8 detects dimers of the HIV viral protease.
The viral protease dimerizes only when the new viral particles are exiting the host cell, and by delaying the process the virus avoids recognition of producer cells by CARD8.
A team at Washington University in St. Louis found that treatment with efavirenz and rilpivirine, inhibitors of the HIV reverse transcriptase, somehow trigger the premature dimerization of protease inside infected cells and reinstate the innate immune response mediated by CARD8 in HIV producer cells, leading to pyroptosis.
Researchers validated the use of efavirenz in HIV infected patients by showing that when the inhibitor is added to the regime of a cohort of infected people that were successfully controlling the virus, the HIV latent reservoir is significantly reduced in 4 months (20% to 50%) in the majority (6 of 7) of the participants.
Merck reported in 2023 the development of a novel reverse transcriptase inhibitor that is an order of magnitude more potent than efavirenz at dimerizing the viral protease in vitro.
It is expected that it will be tested in the future for its efficacy in reducing the latently infected viral reservoir.
The findings highlight the possibility of creating new combinations of antiretrovirals including dimerizers of the HIV protease that might facilitate reduction of viral reservoir pool in the presence of latency reversal agents.”
Stay updated with Hemostasis Today.
-
May 12, 2026, 16:46Tagreed Alkaltham: Why Apheresis Matters in Modern Transfusion Medicine
-
May 12, 2026, 16:37Reinhold Kreutz: Cardiovascular Burden in Acute Intermittent Porphyria Needs Greater Awareness
-
May 12, 2026, 16:33Pablo Corral: The Truth About Very Low LDL-Cholesterol
-
May 12, 2026, 16:24Mildred Lundgren: We Must Talk About the Invisible Causes of Stroke
-
May 12, 2026, 16:17Irene Scala: The Sex Disparities In Access to Acute Stroke Treatments In Italy
-
May 12, 2026, 16:04May Nour: UCLA Health Mobile Stroke Unit Becomes The 1st In The World to Perform mCTA In the Field
-
May 12, 2026, 15:57Leonardo Roever: Prognostic Impact of Lipoprotein(a) and CAR in Elderly Acute Ischemic Stroke Patients
-
May 12, 2026, 15:54Bruno Pougault: Prioritizing Laboratory Tests in Resource-Limited Emergency Care
-
May 12, 2026, 15:37Jennifer Holter Chakrabarty: Supporting the Next Generation of Hematology Researchers